Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Maintains $19 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains a Perform rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and keeps the price target at $19.
May 06, 2024 | 11:44 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Oppenheimer maintains a Perform rating on ACADIA Pharmaceuticals with a $19 price target.
The reaffirmation of the Perform rating and the $19 price target by Oppenheimer suggests a neutral outlook on ACADIA Pharmaceuticals' stock in the short term. This indicates that the analyst sees the stock performing in line with market or sector performance without significant positive or negative changes.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100